Association of the rs2279744 Promoter Polymorphism in the MDM2 Gene with Breast Cancer in a Mexican Population

Maria Guadalupe Márquez-Rosales1,2, José Sánchez-Corona1, Luis Eduardo Figuera1, Héctor Montoya-Fuentes1, Guillermo Moisés Zúñiga-González2, Ana María Puebla-Pérez3 and Martha Patricia Gallegos-Arreola4*

1Molecular Medicine Division, Western Biomedical Research Center, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico
2Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico
3Immunopharmacology Laboratory, Exact and Engineering Sciences University Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
4Genetics Division, Western Biomedical Research Center, Western National Medical Center, Guadalajara, Jalisco, Mexico

Abstract

Introduction: The MDM2 gene plays an important role as a negative regulator of the p53 tumor suppressor. Data on polymorphisms in the MDM2 gene have revealed associations with cancer, particularly for the rs2279744 promoter polymorphism (309 T > G), which attenuates the P53 pathway and promotes tumorigenesis in the mammary gland.

Material and Methods: We examined the role of the MDM2 309 T > G polymorphism through a comparison of the genotypes of 408 healthy Mexican women with those of 529 Mexican women with breast cancer (BC).

Results: The genotype frequencies of the MDM2 309 T > G polymorphism in controls and BC patients were 25% and 23% for T/T (wild type), 50% in BC and controls for T/G, and 25 and 27% for G/G (polymorphic type), respectively. The obtained odds ratio (OR) was 1.07, with a 95% confidence interval (95% CI) of 0.79-1.45, p = 0.64 for the T/G-G/G genotypes. The association was evident when the distributions of the G/G genotypes in patients exhibiting the following characteristics were compared: breastfeeding >6 months (OR 2.1, 95% CI 1.3-3.4, p = 0.002), obesity (OR 1.8, 95% CI 1.2-2.7, p = 0.003) and high GGT levels (OR 1.7, 95% CI 1.1-2.5, p = 0.012). The genotype G/G of the MDM2 309 T > G.

Conclusions: The MDM2 309 T > G polymorphism was associated with BC susceptibility, particularly in breastfeeding, obesity and high GGT levels in the analyzed Mexican population.

Keywords: Rs2279744; MDM2; Polymorphism; Breast cancer; Mexican population

Introduction

Between the developing countries of the world, breast cancer (BC) is one of the most common diseases and is considered a public health problem [1]. The incidence rates of cancer vary in different ethnic groups [2]. In Mexico, BC is one of the five highest causes of death in women >25 years old [3], with an incidence of 15 per 100,000 Mexican women [4]. This statistic has increased within the last 7 years, and it is now one of the main causes of death among working-aged women [5].

A study of cancer incidence projection to 2030 conducted in Mexico estimates approximately 13,981 new cases per year, in which 38% of the women were >68 years old [6]. BC is considered a multifactorial disease, potentially resulting from a combination of abnormal gene interactions and environmental factors [7,8]. Therefore, the elucidation of genetic variants among different ethnic groups might contribute to explaining the progression of cancer and the chemotherapy response.

The mouse double minute 2 (MDM2) gene homolog or the E3 ubiquitin-protein ligase MDM2 gene is located on chromosome 12q15, comprising twelve exons. This gene encodes a protein of 491 amino acids that contains several conserved structural domains, including an N-terminal p53 interaction domain, a central acidic domain, a Zinc finger domain and a C-terminal RING domain. The RING domain confers E3 ubiquitin ligase activity and is sufficient for E3 ligase activity in Mdm2 RING auto ubiquitination. The MDM2 protein functions as a negative regulator of p53 tumor suppressor activity and an E3 ubiquitin ligase for p53 degradation and possesses several binding sites for other tumor suppressors. The increased MDM2 expression in tumors suggests that the levels of MDM2 inactivate the apoptotic and cell cycle arrest functions of the p53 tumor suppressor, similar to the deletion or mutation of p53, common events observed in tumors [9].

The MDM2 gene exhibits several reported polymorphisms, one of which is rs2279744, a single nucleotide polymorphism in the first intron that increases MDM2 expression 2-to 3-fold. It has been suggested that the G/G polymorphism might enhance promoter recognition through the transcription factor Sp1, which in turn elevates MDM2 expression and attenuates the p53-mediated apoptotic response to cellular stresses, including DNA damage [10].

Thus, polymorphisms in the MDM2 gene might impair the function of the p53-mediated stress response. Some studies have demonstrated the overexpression of MDM2 in human tumors, associated with poor prognosis [11,12]; however, other studies have not shown evidence of these associations [13-18]. Because the evidence is contradictory, the aim of the present study was to determine whether there is an association between the rs2279744 polymorphism in the MDM2 gene and BC in Mexican women.

Materials and Methods

DNA was extracted from peripheral blood leukocytes in blood samples obtained from 408 healthy women recruited as volunteer blood donors using standard protocols [19]. These volunteers were not matched by age with the patient group. Blood samples were also collected from 529 patients with a clinical and histological diagnosis of breast cancer.

*Corresponding author: Martha Patricia Gallegos-Arreola, Division of Genetics, CIBO, IMSS, Sierra Mojada 800, Col. Independencia, Guadalajara, Jalisco 44340, Mexico. Tel: +52 33 36170060 Ext: 31936; E-mail: marthapatriciagallegos08@gmail.com

Received December 24, 2015; Accepted March 17, 2016; Published March 21, 2016


Copyright: © 2016 Márquez-Rosales MG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
BC from June 2010 to May 2015. All individuals included in the present study were residents of the metropolitan area of Guadalajara. All samples were obtained after written informed consent was provided, and this study was approved through ethical committee 1305 of the Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social (IMSS). This study was conducted according to national and international ethical standards. The clinical and demographic data were obtained using written questionnaires. All of the patients were also interviewed to determine the occupational exposure and the use of pharmacological therapies. The BC patient database and patient DNA samples were examined for other polymorphisms [7,8,20-23].

The amplification of the rs2279744 polymorphism in the MDM2 gene was performed via PCR using the following primers: 5’-GAT TTC GGA CGG CTC TCG CGG C-3’ and 5´-CAT CCG GAC CTC CCG GGA CGG CTC TCG CGG C-3’ [24]. The PCR amplifications were performed in a total volume of 15 μL containing 0.2 mM dNTPs (Invitrogen, Carlsbad, CA USA), 5 pmol of primers, 2.0 mM MgCl2, 10% BSA, 2.5 U of Taq polymerase (Invitrogen, Carlsbad, CA USA), and 50 ng of genomic DNA. The following PCR conditions were used: 95°C (4 min), followed by 35 cycles at 95°C (40 sec), 58°C (40 sec) and 72°C (50 sec), with a final extension at 72°C (7 min). Using this procedure, two fragments of 178 and 479 bp were obtained. To facilitate allelic discrimination, the amplified products were separated on 8% polyacrylamide gels of 178 and 479 bp. The amplified products were separated on 8% polyacrylamide gels (19:1), followed by silver staining [25]. We determined that the 121 bp fragment alone represented the wild-type genotype (T/T), while the 121, 104 and 17 bp fragments indicated the heterozygous genotype (T/G), and the 104 and 17 bp fragments represented the homozygous polymorphic genotype (G/G).

The allele frequencies were obtained through direct counting. The Hardy-Weinberg equilibrium was tested using a goodness-of-fit Chi square test to compare the observed genotype frequencies with the expected frequencies among control subjects. Odds ratios and 95% confidence intervals (CI) were also calculated. A two-sided p < 0.05 was considered statistically significant. All statistical analyses were performed using PASW Statistic Base 18 software, 2009 (Chicago, IL).

Results

The comparative epidemiological data from BC patients and control individuals are shown in Table 1. In the patient group, the average age was 54.36 years, ranging from 17 to 89 years. Menarche

<table>
<thead>
<tr>
<th>BC patients (n=528)</th>
<th>Controls (n=408)</th>
<th>OR (IC 95%) p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) Mean (SD)</td>
<td>54.36 (11.51)</td>
<td>46.14 (14.64)</td>
</tr>
<tr>
<td>Menarche (years) Mean (SD)</td>
<td>12.57 (1.63)</td>
<td>12.30 (0.82)</td>
</tr>
<tr>
<td>Menarche (range)</td>
<td>7-10 (n)</td>
<td>11-13 (n)</td>
</tr>
<tr>
<td>Tobacco Consumption</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>(n)</td>
<td>(148)</td>
<td>(381)</td>
</tr>
<tr>
<td>(%)</td>
<td>28</td>
<td>32</td>
</tr>
<tr>
<td>Alcohol Consumption</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>(n)</td>
<td>(146)</td>
<td>(381)</td>
</tr>
<tr>
<td>(%)</td>
<td>28</td>
<td>32</td>
</tr>
</tbody>
</table>

*SD: standard deviation, NS: no significant difference, *OR (odds ratio) from the adjusted regression analysis.

Table 1: Demographic data for the study group.

Presented at a mean age of 12.57 years in patients and 12.30 years in control individuals.

Table 2 shows the general clinical characteristics of the patient group. We observed that 24% of the patients exhibited diabetes mellitus (DM)-arterial hypertension (AH), 29% of the patients presented breast fibrosis-myoamotasis-hysterectomy; 43% of the patients were luminal A type, 89% of the patients displayed ductal histology, and 66% of the patients exhibited stage III-IV tumors.

The genotype and allele frequencies of the rs2279744 polymorphism in the MDM2 gene were similar between control and patient groups (p > 0.05) (Table 3). The genotype distribution in the control group was 89% T/T, 9% T/G, and 2% G/G. The genotype distribution in the patient group was 81% T/T, 15% T/G, and 4% G/G. The difference in genotype distribution between the two groups was statistically significant (p < 0.001).

Table 2: Clinical data from patients with BC.

<table>
<thead>
<tr>
<th>Laboratory test</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/ dl)</td>
<td>13.01 (5.81)</td>
</tr>
<tr>
<td>Chemotherapy response</td>
<td>37.29 (5.14)</td>
</tr>
<tr>
<td>Tumor markers</td>
<td>Platelets (mm³)</td>
</tr>
<tr>
<td>Luminal A</td>
<td>360.45 (149.02)</td>
</tr>
<tr>
<td>Basal</td>
<td>38.14 (52.31)</td>
</tr>
<tr>
<td>No</td>
<td>40.09 (45.37)</td>
</tr>
<tr>
<td>Ki67</td>
<td>544.89 (571.89)</td>
</tr>
<tr>
<td>TPS3</td>
<td>68.62 (192.81)</td>
</tr>
</tbody>
</table>

*Positive familial history of cancer and leukemia in first and second degree relatives of patients. Transaminase (SGOT), Glutamic pyruvic transaminase (SGPT), Lactate dehydrogenase (LDH), Alkaline phosphatase (ALP), Gamma glutamyl transferase (GGT) according to OMS classifications. (Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Ginebra (Suiza): World Health Organization, 2004).
extensively studied in relation to many types of cancers, including BC. This polymorphism has been proposed as a negative regulator of the P53 tumor suppressor pathway, influencing the binding of MDM2 to P53, thereby inhibiting the activity of this protein, resulting in the degradation of this tumor suppressor gene expression, affecting the progression and proliferation of BC tumor cells. It has also been suggested that the aromatization of estrogen and androgens in susceptible to environmental carcinogens, and the stimulation of ovulatory cycles through prolonged time with hormonal effects in working-aged women. These facts are consistent with the observations in the present study and other studies, where the average age of BC patients was 54.36 (± 11.51 years) and was found to be a risk factor. Multiple studies have previously observed these associations [1,2,5,7,39]. In addition, some genetic factors have been implicated in the association of obesity with cancer, such as the stability of the p53-MDM2 interaction, including posttranslational modifications of p53.

The genetic regulation of MDM2 in P53 tumor suppressor activity in cancer has been the focus of many investigations. MDM2 has been proposed as a negative regulator of the P53 tumor suppressor pathway, influencing the binding of MDM2 to P53, thereby inhibiting the activity of this protein, resulting in the degradation of this tumor suppressor via the ubiquitination pathway [28]. The presence of the rs2279744 polymorphism in the promoter region up-regulates the expression of MDM2 through affinity for the SP1 transcription factor, inhibits the transcription of p53 activity, induces tumor promotion in the mammary gland and might impact BC oncogenesis. This polymorphism has been extensively studied in relation to many types of cancers, including BC [28-30]. However, findings from these studies have been inconsistent [13-18].

Furthermore, the data obtained in the present study also showed that the genotype distribution of the rs2279744 MDM2 polymorphism followed Hardy-Weinberg equilibrium (P > 0.05). The genotype G/G frequencies (25%) of the rs2279744 polymorphism in the control group were similar to those previously reported in Indian (28%) [12], Chinese (25.8%) [31], and Turkish populations (29.6%) [32]. Several authors have studied the MDM2 309 T > G polymorphism, although these studies did not analyze the same markers, and the studied groups have had different compositions (e.g., regarding female, male, menopause, tumor stages, ethnic backgrounds, and ages). Consequently, there are conflicting results regarding this association, with several studies observing a decreased risk of BC in association with the MDM2 309 T > G polymorphism [13-18,33]. We observed similar genotype frequencies of the G/G polymorphism in the control and BC groups (P > 0.05). Singh et al. [34] did not observe an association of the MDM2 309 T > G polymorphism with breast cancer in a study of 104 BC patients and 105 controls from the Indian population. In addition, Schmidt et al. (2007 and 2009) [13,14] did not observe an association of the MDM2 309 T > G polymorphism with breast cancer risk and age at the onset of breast cancer in a pooled series of 5,191 cases and 5,834 controls from the Breast Cancer Association Consortium (BCAC). Cox et al. [15] did not observe a risk association of the MDM2 309 T > G polymorphism with breast cancer in a study on the health of nurses. Other studies have also shown no evidence of this association [16-19].

In the present study, we also observed an association of the G/G genotype as a risk factor in BC patients, showing breastfeeding (>6 months), obesity (BMI 25-29.9) and high GGT plasma levels. The relationship between breastfeeding, obesity and BC is complex and has been associated with factors including genetic predisposition, social class, exercise, alcohol consumption and diet [7-8,21-23]. The data obtained from 47 epidemiological studies in 30 countries, including 50302 women with invasive breast cancer and 96973 controls, reported that women who breast feed longer are more protected against breast cancer, and the lack of or short duration of breastfeeding typical of women in developed countries primarily contributes to the high incidence of breast cancer in these countries [34].

Table 4 shows that the G/G genotype was associated with breastfeeding (<6 month) (OR 2.11, 95% CI 1.31-3.40, p = 0.002), obesity (OR 1.8, 95% CI 1.22-2.75, p = 0.003) and higher GGT levels (OR 1.7, 95% CI 1.22-2.75, p = 0.003) as risk factors.

The data obtained from the survival analysis using the Kaplan-Meier method showed that differences in the diagnosis period and age of BC in patients with G/G genotypes were not statistically significant (log-rank test, p = 0.914) (data not shown).

Discussion

BC is a multifactorial disease with a complex etiology and is considered a major public health problem in industrialized countries. In Mexico, BC is currently one of the leading causes of death in working-aged women [2,5,7,8,20-23]. These facts are consistent with the observations in the present study and other studies, where the average age of BC patients was 54.36 (± 11.51 years) and was found to be a risk factor. Multiple studies have previously observed these associations [1,2,5,26].

Gene polymorphisms with a low penetrance are risk factors in BC [2,5,7,8,17-23,27].

The genetic regulation of MDM2 in P53 tumor suppressor activity in cancer has been the focus of many investigations. MDM2 has been proposed as a negative regulator of the P53 tumor suppressor pathway, influencing the binding of MDM2 to P53, thereby inhibiting the activity of this protein, resulting in the degradation of this tumor suppressor via the ubiquitination pathway [28]. The presence of the rs2279744 polymorphism in the promoter region up-regulates the expression of MDM2 through affinity for the SP1 transcription factor, inhibits the transcription of p53 activity, induces tumor promotion in the mammary gland and might impact BC oncogenesis. This polymorphism has been extensively studied in relation to many types of cancers, including BC [28-30]. However, findings from these studies have been inconsistent [13-18].
Studies on obese rodents fed high-fat, high-sucrose diets suggest that tumor suppressor p53 modifications might play a role in obesity [40,41]. Other studies have shown that the high concentration of hepatic p53 is provocative for conditions of obesity or fatty liver, playing a role in regulation through MDM2-p53 and contributing to the development of tumorigenesis [40-42]. Although the precise mechanisms underlying the relationship between the regulation of MDM2 to p53 and obesity remain unclear, studies have shown that p53 gene is activated in the adipocytes of ob/ob mice, functioning in the mechanisms of dysregulated gene expression in the adipose tissue of obese animals, and MDM2, as a negative regulator of p53, also participates in the dysregulated gene expression in adipose tissues and participates in the promotion of BC tumorigenesis [41,42].

We also observed an association of the G/G genotypes of BC patients with elevated levels of GGT as a risk factor. However, there are no available studies addressing the influence of the G/G genotype of the MDM2 gene and the high levels of GGT in BC patients. This observation could likely reflect the participation of GGT in cellular glutathione metabolism, cell proliferation, apoptosis, tumor progression, invasion and cancer cell drug resistance. The expression of GGT is often increased in tumors and has been suggested as a biomarker [8,43-45]. The GGT enzyme is constitutively expressed in various organs, and this expression is significantly elevated in premalignant lesions or malignant tumors; therefore, GGT is considered to confer a favorable environment for the growth and survival of neoplastic cells [44,46]. An increased level of GGT has been associated with higher rates of DNA damage and different cancers [45-47]. Previous studies have shown associations between cell surface GGT and the tetraspan 4 family, including CD53, CD81 and CD82, as molecules that mediate the signal transduction involved in the modulation of cell responses [48]. Fenton et al. suggested that premenopausal women with high serum or elevated levels of GGT are at increased risk of breast cancer and might benefit from close surveillance, potentially through breast magnetic resonance imaging. Serum GGT might indicate previous exposure to carcinogens and lead to the identification of DNA adducts involved in mammary carcinogenesis [44]. Thus, GGT could reflect previous exposure to as yet unknown carcinogens initiating breast carcinogenesis.

However, the regulation mechanism of MDM2-p53 likely influences the overexpression of GGT in BC, in addition to other factors, such as metastatic nodes, tumor markers, menopause, diagnosis period, tumor stage, obesity, and treatment resistance [7,8,20]. This response might be affected through polymorphisms in the MDM2 gene that can indirectly contribute to the modification of MDM2 activity, producing changes in DNA and subsequently participating in neoplastic progression.

Scott suggested that "genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time, and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome" [49].

Conclusion

The results of the present study revealed that the frequencies of the homozygous G/G genotype of the MDM2 309 T > G polymorphism were not significantly different between control and BC patients. However, the differences were most evident in patients breast feeding >6 months, exhibiting obesity, and exhibiting high levels of GGT, as risk factors that might significantly contribute to BC susceptibility in the analyzed sample from a Mexican population. Nevertheless, further studies are required to confirm or reject these observations.

Competing Interests

The authors report no financial conflicts of interest. The authors are responsible for the content and drafting of this manuscript.

Author Contributions

All of the authors contributed to the manuscript, the conception and design of the study and the acquisition, analysis and interpretation of the data.

Acknowledgments

The authors would like to thank Dr. Efrain Salas and the nurses from UMAE Hospital de Gineco-Obstetricia, CMNO, IMSS for facilitating sample collection. This research was financially supported in part through FIS/IMSS/PROT/G15/1463 grants.

This research was financially supported in part through FIS/IMSS/PROT/G15/1463 grants.

References

30. Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ (2009) Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 9: 13.
49. Scott R (2010) Have the roles of two functional